Two poster presentations at the ESMO Conference at Lugano this week showed that the drug, called Abiraterone, reduced the levels of prostate specific antigen (PSA) in men who have failed initial treatment and in men who have failed treatment with Taxotere. Abiraterone inhibits the production of male androgens by blocking the enzyme CYP450c17. Without this [...]
There is great news for those of us who are on a hormone blockade. The latest reported from the 2007 meeting of the American Society of Clinical Oncology says that Intermittent Androgen Suppression (IAS) is just as effective as continuous therapy. The study cited was a randomized multi-center trial with men diagnosed with advanced prostate [...]
The following appeared in the Friday, June 8th edition of Health Day News. Those of us who are on a hormone blockade, or who are contemplating starting a blockade need to be aware of this vital issue. Although the study only looked at older men, those of us who are on the younger side should [...]
Despite the fact that we have already had a radical prostatectomy, at some point in time one third of us will receive that dreaded telephone call from our doctor.... our PSA has reappeared! Once again, we start the process of climbing into the tube for an MRI, we have a bone scan and of course [...]
The American Society of Clinical Oncology has recently updated its clinical practice guidelines for the management of initial hormone therapy with men with advanced P.C. The guide line panel found that there is a 17% reduction in the mortality rate from prostate cancer if hormone therapy is started early in the disease process, however, the [...]